Type 1 Diabetes and the Immune System
Type 1 diabetes is an autoimmune condition, meaning the immune system mistakenly attacks the body’s own healthy cells. In this case, the immune system targets the beta cells in the pancreas. These beta cells are responsible for making insulin, the hormone that helps move sugar from the bloodstream into the body’s cells for energy.
When beta cells are damaged, the body cannot produce enough insulin on its own. This is why people with type 1 diabetes depend on insulin therapy to manage blood sugar levels.
While insulin is essential, researchers continue to explore ways to support the body earlier in the disease process. One area of interest is whether mesenchymal stem cells (MSCs) may help calm immune activity and protect remaining beta cell function after diagnosis.
Why MSCs Were Studied
MSCs are being researched because they release helpful signals that can communicate with immune cells and damaged tissues. In autoimmune conditions, this is especially important because the problem is not only tissue damage, but also an immune response that is out of balance.
In type 1 diabetes, researchers are interested in whether MSCs may help shift the immune system away from inflammation and toward a calmer, more balanced state.
The goal is not to replace insulin or claim a cure. Instead, this study explored whether MSC therapy could be safe and possibly help improve blood sugar control, reduce low blood sugar episodes, and support immune regulation in newly diagnosed patients.
How the Clinical Trial Worked
This study was a phase I/II clinical trial, which means it looked at both safety and early signs of benefit. The trial included 21 patients, ages 8 to 40, who had been diagnosed with type 1 diabetes within about six weeks before enrollment. Patients were randomly assigned to receive either MSC therapy or placebo.
The MSCs used in this study came from each patient’s own bone marrow. This is called an autologous treatment, meaning the cells came from the same person who received them.
Patients in the MSC group received two intravenous infusions of bone marrow-derived MSCs. Each dose was 1 million cells per kilogram of body weight, given at the start of treatment and again three weeks later. The placebo group received saline.
Researchers followed the patients for at least one year and measured safety, blood sugar control, insulin use, C-peptide levels, immune markers, low blood sugar episodes, and quality of life.
What the Study Found
The study reported encouraging safety findings. There were no major complications or deaths during the study. The researchers also reported no major treatment-related adverse events. One patient had a stronger allergic-type skin reaction during the first infusion, but it improved with treatment.
One of the most meaningful findings involved hypoglycemia, or low blood sugar. Low blood sugar can be stressful and potentially dangerous for people with type 1 diabetes. In this study, patients who received MSC therapy had significantly fewer mild and moderate low blood sugar episodes compared with the placebo group.
The MSC group also showed improvement in HbA1c at 12 months. HbA1c is a common blood test that reflects average blood sugar levels over time. Lower HbA1c can suggest better long-term blood sugar control.
The researchers also looked at C-peptide, a marker that helps show how much insulin the body is still making naturally. C-peptide levels showed a trend that favored MSC treatment, although the difference between groups was not statistically significant in the main comparison.
Insulin needs were also measured, but the study did not find a significant difference in insulin use between the MSC and placebo groups.
A Possible Immune-Balancing Effect
One of the most interesting parts of this study was the immune response.
After MSC treatment, researchers observed changes in immune-related markers. Some inflammation-related signals decreased, while certain anti-inflammatory signals increased. The study also reported an increase in regulatory T cells shortly after treatment. Regulatory T cells help keep the immune system from overreacting and are important in autoimmune conditions.
In simpler terms, MSC therapy appeared to influence the immune system in a direction that may be more balanced and less inflammatory.
This matters because type 1 diabetes is driven by immune system activity against the pancreas. A therapy that helps support immune balance early after diagnosis may be useful to study further.
Why Timing May Be Important
The researchers also compared patients who received MSCs earlier after diagnosis with those who received them later. Early treatment appeared to show stronger improvements in HbA1c, C-peptide, and immune markers.
This supports the idea that timing may matter. In newly diagnosed type 1 diabetes, some beta cells may still be functioning. Researchers are interested in whether earlier immune support could help preserve more of that remaining function.
Again, this does not mean MSC therapy reverses type 1 diabetes. But it does suggest that early intervention may be an important area for future research.
What This Means for Regenerative Medicine
This study is important because it adds to the growing research on MSCs for immune-related conditions. While many people associate regenerative medicine with joints, injuries, or tissue repair, MSCs are also being studied for how they communicate with the immune system.
For type 1 diabetes, this study suggests MSCs may have potential as a supportive therapy focused on immune balance, blood sugar stability, and protection of remaining beta cell activity.
The trial was small, so larger studies are needed. Future research can help clarify who may benefit most, how long effects may last, and whether different MSC sources or dosing approaches could improve outcomes.
Main Takeaway
This phase I/II clinical trial found that bone marrow-derived MSC therapy was generally well tolerated in newly diagnosed type 1 diabetes patients. The study reported fewer low blood sugar episodes, improved HbA1c at 12 months, and signs of a more balanced immune response after treatment.
While MSC therapy is not a cure for type 1 diabetes and did not significantly reduce insulin needs in this trial, the findings support continued research into regenerative and immune-supportive approaches that may help patients earlier in the disease process.
Source
Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, Hedayati Asl AA, Abbasi Kakroodi F, Jaroughi N, Mohseni Meybodi MA, Setoodeh A, Abbasi F, Hosseini SE, Moeini Nia F, Salman Yazdi R, Navabi R, Hajizadeh-Saffar E, Baharvand H. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. Stem Cell Research & Therapy. 2022 Jun 20;13:264. doi: 10.1186/s13287-022-02941-w. PMID: 35725652; PMCID: PMC9208234. https://pmc.ncbi.nlm.nih.gov/articles/PMC9208234/
Related Treatment Pages